

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2002 (03.01.2002)


PCT

(10) International Publication Number
WO 02/00199 A1

- (51) International Patent Classification⁷: **A61K 9/16** (74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (21) International Application Number: **PCT/GB01/02923**
- (22) International Filing Date: **29 June 2001 (29.06.2001)** (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
0016040.8 **29 June 2000 (29.06.2000)** **GB**
- (71) Applicant (*for all designated States except US*): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **LANCASTER, Robert, William** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **SINGH, Hardev** [IN/GB]; GlaxoSmithKline, Temple Hill, Dartford, Kent DA1 5AH (GB). **THEOPHILUS, Andrew, Lewis** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: **NOVEL PROCESS FOR PREPARING AND HARVESTING CRYSTALLINE PARTICLES**



(57) Abstract: The present invention relates to a novel process for preparing and harvesting crystalline particles, particularly particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy.

WO 02/00199 A1



— *entirely in electronic form (except for this front page) and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Novel process for preparing and harvesting crystalline particles

This invention relates to a novel process for preparing crystalline particles, particularly particles of defined particle size distribution, especially particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy.

Industrial processes for production of many products, particularly pharmaceutical products, require the preparation of pure substances of a defined particle size distribution. Pure substances are frequently prepared by precipitation from solutions of lesser purity. When precipitation takes place relatively slowly (e.g. over a matter of hours), crystals are grown which are frequently of a non-uniform shape and relatively large size.

In the field of inhalation therapy, therapeutic molecules are generally desired of a particle size "suitable for inhalation", which is a term generally taken to indicate an aerodynamic diameter between 1 and 10 μm , especially 1 and 5 μm , particularly 1 and 3 μm . Carrier molecules (such as lactose) for inhaled therapeutic preparations are typically desired of a significantly larger aerodynamic diameter so that they do not penetrate into the upper respiratory tract to the same degree as the active ingredient and an aerodynamic diameter of 100 to 150 μm is generally considered suitable. However this is a generalisation and for some purposes it may well be preferred to use a lower particle size for the carrier, even one comparable to that of the therapeutic substance.

Outside of the inhaled area, modification of the habit and size of crystals is a valuable tool in adjusting and optimising pharmaceutical and biological properties such as flow characteristics, dissolution rate and bioavailability.

Particles of the desired particle size for inhalation therapy are conventionally prepared by milling or micronisation. These processes, depending on the precise conditions adopted, are capable of generating particle distributions which include fractions having particles with the appropriate size. Milling is suitable for preparing particles of the larger size indicated above and micronisation of the smaller size indicated above. However, there are a number of disadvantages associated with milling and micronisation processes including that the fraction having the desired particle size may be relatively small, that there may be generated a significant fraction of particles that are finer than is desired (which may be deleterious e.g. if it affects bioavailability) and that product losses generally may be considerable (e.g. through coating of the machinery). A further property of micronised products is that the surfaces of the particles generated are generally substantially amorphous (i.e. have minimal crystallinity). This may be undesirable when there exists a tendency for the amorphous regions to convert to a more stable crystalline state. Furthermore micronised or milled products may be more susceptible to moisture uptake than crystalline products. Micronisation and milling processes also suffer from the disadvantages that they are relatively energy intensive and require containment and other measures to avoid the risk of dust explosion.

International patent application PCT/GB99/04368 (filed but not published before the priority date of this application) describes a process and apparatus for preparing particles which comprises mixing in the presence of ultrasonic radiation a flowing solution of a substance in a liquid solvent with a flowing liquid antisolvent for said substance. International patent application PCT/GB00/04237 describes a process which comprises admitting a stream of a solution of a substance in a liquid solvent and a stream of liquid antisolvent for said substance tangentially into a cylindrical mixing chamber, consequently

causing a vortex which results in precipitation of crystalline particles. However, the disadvantage with these 2 processes is that particle growth or agglomeration may occur in the course of isolating the particles from the solvent/anti-solvent mixture. We have now invented an improvement to these processes which is less susceptible to the above mentioned disadvantage.

Thus, according to a first aspect of the invention there is provided a process for preparing crystalline particles of a substance which comprises mixing a flowing solution of the substance in a liquid solvent with a flowing liquid antisolvent for said substance in order to generate a suspension of crystalline particles in the solvent/anti-solvent mixture, and collecting the resultant crystalline particles generated characterised in that the solvent is more volatile than the anti-solvent and that the process further comprises the step of removing the solvent from the solvent/anti-solvent mixture prior to collection of the crystalline particles.

In a first preferred embodiment of the present invention said mixing comprises mixing in a continuous flow cell in the presence of ultrasonic radiation.

In a second preferred embodiment of the present invention said mixing comprises admitting a stream of solution of the substance in a liquid solvent and a stream of liquid antisolvent for said substance tangentially into a cylindrical mixing chamber having an axial outlet port such that said streams are thereby intimately mixed through formation of a vortex and precipitation of crystalline particles of the substance is thereby caused.

Preferably, the solvent will be miscible with the anti-solvent.

Preferably the step of removal of solvent does not give rise to removal of anti-solvent to an appreciable extent. More preferably the solvent and anti-solvent are removed in separate (e.g. sequential) steps.

- 5 Preferably, the step of removing the solvent is achieved by distillation at or below atmospheric pressure, especially vacuum distillation.

According to a further aspect of the present invention, the step of removing the solvent from the solvent/anti-solvent mixture prior to collection of the crystalline particles comprises the step of:

10

- (a) distillation of the suspension of crystalline particles in the solvent/anti-solvent mixture at or below atmospheric pressure in order to remove the solvent;

and the step of collection of the crystalline particles comprises the steps of:

- 15 (b) cooling the resultant suspension of crystallisation particles in the anti-solvent; and
- (c) collecting crystalline particles by removal of the antisolvent from the cooled suspension.

20 It will be appreciated that the solvent removal step refers to the removal of a significant proportion of the solvent from the solvent/antisolvent mixture. Preferably, all or substantially all solvent is removed. The benefits of the invention are expected to be greatest when solvent is removed to the greatest extent.

25

Preferably, in step (b) the suspension of crystalline particles obtained in step (a) will be cooled to freezing point. Also preferably, in step (b) the suspension of crystalline particles obtained in step (a) will be cooled to freezing point using a

solid carbon dioxide cooling bath containing a suitable solvent eg. acetone, IMS or methanol.

Where possible, preferably the antisolvent will be water. Preferably, in step (c)
5 the removal of the antisolvent from the cooled suspension is achieved by freeze drying.

The process of the present invention has the advantage of maintaining the original particle diameter of the particles of substance achieved by
10 crystallisation. Conventional collection techniques involve further incubation of the particles in the solvent/antisolvent mixture which may result in undesirable effects such as crystal growth. Wherein the particles are prepared for inhalation therapy, crystal growth is disadvantageous because the particles may grow to a diameter such that they may not be effectively delivered to the lower respiratory
15 airways.

The advantages that the invention may possess include the fact that the process may be performed in a continuous manner without requirements for batch processing, that the process may be scaled up with relative ease and that the
20 process is capable of producing particle size distributions of very high uniformity index.

Surprisingly, the present invention provides processes for removing the solvent from the solvent/antisolvent mixture in order to prevent crystal growth, and as
25 demonstrated in the Examples, also results in particles with more refined particle sizes than achieved with conventional harvesting techniques. Furthermore, when the antisolvent is water, once the solvent has been removed from the solvent/antisolvent mixture (by either procedure) and the mixture is cooled to freezing point, the freeze drying step ensures that the water molecules

sublime from the mixture leaving only particles containing the desired substance(s).

The process of the present invention is particularly suitable for preparing particles of substances which are pharmaceutical or carrier substances suitable for inhalation therapy.

Substances suitable for inhalation therapy include substances applied topically to the lung and nose.

Examples of pharmaceutical substances suitable for inhalation therapy include analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone (eg. as the dipropionate), fluticasone (eg. as the propionate), flunisolide, budesonide, rofleponide, mometasone (e.g. as the furoate) or triamcinolone (e.g. as the acetonide); antitussives, e.g., noscapine; bronchodilators, e.g., albuterol (eg. as the sulphate), salmeterol (eg. as the xinafoate), ephedrine, adrenaline, fenoterol (eg. as the hydrobromide), formoterol (e.g. as the fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (eg. as the acetate), reproterol (eg. as the hydrochloride), rimiterol, terbutaline (eg. as the sulphate), isoetharine, tulobuterol or (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy] hexyl]methyl] benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (e.g. as the bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon; and

salts, esters and solvates of any of the above. Other examples include 4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl] amino]ethyl-2(3H)-benzothiazolone or butixicort and salts and solvates thereof.

Another example of a pharmaceutical substance suitable for inhalation therapy is 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester or a solvate thereof (which compound is especially suitable for administration by the nasal route).

Other examples of pharmaceutical substances suitable for inhalation therapy which are of particular interest are:

(2R,3R,4S,5R)-2-[6-Amino-2-(1S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol or a salt thereof (eg. the maleate salt); and

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-4-methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl)amino) propanoic acid or a salt thereof (eg. as free acid or potassium salt).

Examples of other pharmaceutical substances for which the process according to the invention is useful include compounds to be administered orally such as 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid, 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine and naratriptan (eg. as hydrochloride) and other 5HT-1 agonists such as sumatriptan (eg. as succinate). Another compound of interest is (S)-[2-(1-iminoethylamino)ethyl]-L-homocysteine or a salt or racemate thereof (eg. preferably the 2- isomer).

Pharmaceutical substances as described above include asymmetric molecules which may exist as mixtures of optical isomers (e.g. as racemates) or as purified single enantiomers.

Pharmaceutical substances of particular interest include fluticasone, beclomethasone, salmeterol, salbutamol or an ester, salt or solvate thereof. The substance of most interest is salmeterol xinafoate (including the racemate or the purified r- or s- enantiomers). Fluticasone propionate is also of particular interest.

Examples of carrier substances include lactose.

The solvent and antisolvent liquids will be selected so as to be appropriate for the substance. Preferably, they are readily miscible in the proportions employed. Suitable combinations of solvent/antisolvent include acetone/water, ethanol/IPA, methanol/IPA, methanol/water and reciprocal pairs. Methanol/IPE is also a suitable pairing.

For generation of small particles by the process according to the invention, it is preferred that the difference between the dissolution properties of the solvent and anti-solvent be as great as possible. For reasons of industrial efficiency (particularly in order to reduce the throughput volumes of liquid) it is preferred to use concentrations of substance in solvent which are as high as possible.

Nevertheless the solutions must be stable and not prone to crystallisation before discharge into the continuous flow cell. With this end in mind, it may be preferred to use the solution of the substance in the solvent at elevated temperature. It may also be preferable to cool the anti-solvent.

In order to prevent premature precipitation of the dissolved substance in the lines it will generally be desired to prime the apparatus by first pumping it with solvent. It may be preferred to prime the apparatus by pumping it with heated solvent, particularly when the dissolved substance is close to its solubility limit.

When the substance is fluticasone propionate we prefer the solvent to be acetone and the anti-solvent to be water.

When the substance is salmeterol xinafoate we prefer the solvent to be methanol or acetone (more preferably methanol) and the anti-solvent to be water.

When the substance is salbutamol sulphate we prefer the solvent to be water and the anti-solvent to be IMS.

When the substance is beclomethasone dipropionate we prefer the solvent to be IMS and the anti-solvent to be water.

When the substance is lactose we prefer the solvent to be water and the anti-solvent to be ethanol.

When the substance is budesonide, we prefer the solvent to be methanol and the anti-solvent to be water.

When the substance is formoterol fumarate or terbutaline sulphate we prefer the solvent to be methanol or acetone and the anti-solvent to be water.

When the substance is 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine we prefer the solvent to be methanol and the anti-solvent to be water.

When the substance is 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid we prefer the solvent to be acetone and the anti-solvent to be water.

When the substance is naratriptan hydrochloride we prefer the solvent to be methanol and the antisolvent to be IPE.

When the substance is 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester we prefer the solvent to be acetone and the anti-solvent to be water.

We have found that the method according to the invention is suitable for producing populations of mixtures when the substance is a mixture of substances. When the substance is a mixture the method has particular

advantages since it is capable of producing mixtures of crystalline particles of very high homogeneity without the need for any blending step. When the substance is a mixture the solvent and anti-solvent will have to be appropriate for all components of the mixture. Differential solubilities in the recrystalline mixture tend to result in the output proportions of the mixture differing from the initial proportions in solution in the solvent and so appropriate adjustment of the input proportions to achieve the desired output proportions may be necessary.

The method according to the invention is particularly suitable for producing mixtures of crystalline particles of salmeterol and fluticasone or salts and esters thereof e.g. salmeterol xinafoate and fluticasone propionate. The preferred solvent is acetone. The preferred anti-solvent is water. Recrystallisation from acetone using water as anti-solvent tends to cause an increase in the ratio of salmeterol xinafoate to fluticasone propionate relative to their proportion in solution in acetone. The method is also expected to be suitable for producing mixtures of crystalline particles of formoterol and budesonide or salts and esters thereof e.g. formoterol fumarate and budesonide.

As a further aspect of the invention we provide a population of particles obtainable by a process according to the invention.

Particles of pharmaceutical or carrier substances may be obtained which are suitable for use in a pharmaceutical composition for inhalation therapy, such as dry powder composition (whether containing pure drug, or drug mixed with a carrier such as lactose) or a pressurised liquid formulation (e.g. a formulation comprising a hydrofluoroalkane (HFA) propellant such as HFA134a or HFA227 or a mixture thereof).

Pressurised liquid formulations suitable for metered-dose inhalers will be retained in canisters, typically aluminium canisters (which may be plastics lined) which are provided with a metering valve of appropriate metering volume.

5 It will be appreciated that references to inhalation therapy also extend to administration of pharmaceutical compositions via the nasal route. Formulations suitable for nasal delivery include pressurised (e.g. HFA containing) formulations and non pressurised (e.g. aqueous) formulations which may be metered by the delivery device adapted for administration to the nose.

10

We also provide a pharmaceutical composition comprising a population of particles prepared according to the invention.

15

Apparatus suitable for use in the present invention is illustrated by reference to Figure 1 in which mixing chamber 1 is provided with first inlet port 2 connected to first reservoir 3 containing substance dissolved in solvent and second inlet port 4 connected to second reservoir 5 containing anti-solvent. Pumps 6 and 7 deliver liquid from reservoirs 3 and 5 to mixing chamber 1 at a controlled rate. An ultrasound probe 8 is located in the vicinity of, and just above, inlet port 2.

20

When pumps 6 and 7 are in operation, liquids from reservoirs 3 and 5 are delivered to mixing chamber 1 and are mixed with the aid of magnetic stirrer 9. Liquid containing the particles of substance thus generated flows out of the mixing chamber via exit port 10. The solvent within this flowing suspension is then removed using vacuum distillation 11 according to the present invention.

25

Brief description of the drawings.

Figure 1: Example apparatus according to the invention

The present invention is illustrated by the following non-limiting example:

Examples

Example 1

Distributions of particles of crystalline fluticasone propionate

5 Experimental procedure

The drug substance (fluticasone propionate, FP) (10g) was dissolved in hot acetone (150ml) and then allowed to cool to ambient temperature (20 °C). A flow cell was then charged with a 4:1 mixture of water and acetone respectively. Pump 1 (containing the fluticasone propionate in acetone) was set at a flow rate of 20ml/min. Pump 2 (containing chilled water) was set at 80ml/min. An ultrasound probe was set to deliver approximately 70-75watts of power. When the ultrasound probe and both pumps were turned on, rapid onset of crystallisation occurred.

15 The slurry output was collected in a Bucci flask and concentrated *in vacuo* until all of the acetone had been removed, leaving only aqueous slurry (approximately 50ml). This was then rapidly frozen using a solid carbon dioxide cooling bath containing acetone. The contents of the flask were then freeze dried overnight to give a free flowing fine dry white powder (Example 1A). No sieving or deaggregation of the particles by passing them through a screen was necessary.

25 Control particles were prepared by suspending fluticasone propionate (10g) (obtained from micronisation rather than the process described for Example 1A) in water (50ml) and freezing rapidly using a solid carbon dioxide cooling bath containing acetone. The resultant mixture was then freeze dried overnight to give Example 1B.

Analysis

13

Particles of Examples 1A and 1B were analysed using Malvern laser diffraction particle sizing.

Instrument: Malvern Mastersizer X

Lens: 45mm Reverse Fourier

5 Analysis: 0607 presentation code

Dispersant: Iso Octane / Lecithin 0.05% w/w

Pre dispersion: Sonicate for 3 minutes

Obscuration: 10% to 16%

10 One analysis per sample was carried out. The median particle size (D50), particle size at 90% undersize (D90) and particle size at 10% undersize (D10) were used as responses to characterise the medium, course, and fine particles.

Results

15

Example	D10 (μm)	D50 (μm)	D90 (μm)
1A	1.01	2.86	5.93
1B	1.77	3.65	7.24

The results of this investigation indicate that the process of the present invention produces particles with more refined particle sizes than particles obtained from micronisation.

20

The contents of the above mentioned patent application is herein incorporated by reference.

CLAIMS

1. A process for preparing crystalline particles of a substance which comprises mixing a flowing solution of the substance in a liquid solvent with a
5 flowing liquid antisolvent for said substance in order to generate a suspension of crystalline particles in the solvent/anti-solvent mixture, and collecting the resultant crystalline particles generated characterised in that the solvent is more volatile than the anti-solvent and that the process further comprises the step of removing the solvent from the solvent/anti-solvent mixture prior to collection of
10 the crystalline particles.
- 2 A process according to claim 1 wherein said mixing comprises mixing in a continuous flow cell in the presence of ultrasonic radiation.
- 15 3. A process according to claim 1 wherein said mixing comprises admitting a stream of solution of the substance in a liquid solvent and a stream of liquid antisolvent for said substance tangentially into a cylindrical mixing chamber having an axial outlet port such that said streams are thereby intimately mixed through formation of a vortex and precipitation of crystalline
20 particles of the substance is thereby caused.
4. A process according to any one of claims 1 to 3 wherein the solvent is miscible with the anti-solvent.
- 25 5. A process according to any one of claims 1 to 4 wherein the step of removal of the solvent does not give rise to removal of the anti-solvent.
6. A process according to any one of claims 1 to 5 wherein the solvent and anti-solvent are removed in separate steps.

7. A process according to any one of claims 1 to 6 wherein the step of removing the solvent is achieved by distillation.

5 8. A process according to any one of claims 1 to 7 wherein the step of removing the solvent from the solvent/anti-solvent mixture prior to collection of the crystalline particles comprises the step of:

- 10 (a) distillation of the suspension of crystalline particles in the solvent/anti-solvent mixture at or below atmospheric pressure in order to remove the solvent;

and the step of collection of the crystalline particles comprises the steps of:

- (b) cooling the resultant suspension of crystallisation particles in the anti-solvent; and
15 (c) collecting crystalline particles by removal of the antisolvent from the cooled suspension.

9. A process according to claim 7 or claim 8 wherein the step of removing the solvent is achieved by vacuum distillation.

20 10. A process according to any one of claims 1 to 9 wherein all or substantially all solvent is removed in the solvent removal step.

11. A process according to any one of claims 8 to 10 wherein in step (b) the suspension of crystalline particles obtained in step (a) is cooled to freezing
25 point.

12. A process according to any one of claims 8 to 11 wherein in step (b) the suspension of crystalline particles obtained in step (a) are cooled to freezing

point using a solid carbon dioxide cooling bath containing a suitable solvent eg. acetone, IMS or methanol.

13. A process according to any one of claims 1 to 12 wherein the
5 antisolvent is water.

14. A process according to any one of claims 8 to 12 wherein in step (d)
the removal of the antisolvent from the cooled suspension is achieved by freeze
drying.

10 15. A process according to any one of claims 1 to 14 wherein the process
prepares particles of substances which are pharmaceutical or carrier substances
suitable for inhalation therapy.

15 16. A process according to claim 15 wherein the substance is fluticasone,
beclomethasone, salmeterol, salbutamol or an ester, salt or solvate thereof.

17. A process according to claim 15 wherein the substance is lactose.

20 18. A process according to claim 15 wherein the substance is 6 α , 9 α -
difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-
17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester.

25 19. A process according to claim 16 wherein the substance is fluticasone
propionate.

20. A process according to claim 16 wherein the substance is salmeterol
xinafoate.

21. A process according to claim 13 wherein the substance is a mixture.

22. A process according to claim 21 wherein the substance is a mixture of fluticasone propionate and salmeterol xinafoate.

5

23. A process according to any one of claims 1 to 14 wherein the process prepares particles of substances which may be administered orally.

10

24. A process according to claim 23 wherein the substance is 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid or 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine.

25. A process according to claim 23 wherein the substance is naratriptan hydrochloride.


15

26. A population of particles obtainable by a process according to any one of claims 1 to 25.

20

27. A pharmaceutical composition comprising a population of particles according to claim 26.

FIG.1



A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 32095 A (ASTRA AKTIEBOLAG) 17 October 1996 (1996-10-17) claims 1,12-14,20,21,24,25,28 page 5, line 12 - line 27 page 7, line 7 - line 9 page 8; example 1	1-5,13, 15-17, 19,26,27
P,X	WO 00 38811 A (GLAXO GROUP) 6 July 2000 (2000-07-06) cited in the application figure 1 claims 1,3,11-25 page 6, line 24 -page 7, line 3 --- -/--	1-17, 19-27



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

30 October 2001

Date of mailing of the international search report

08/11/2001

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 44468 A (BRISTOL-MYERS SQUIBB) 3 August 2000 (2000-08-03) figure 1 claim 1 page 4, line 4 - line 13 page 6; example 1 -----	1-7,9, 13,26,27

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9632095	A	17-10-1996	AU	694863 B2	30-07-1998
			AU	5352496 A	30-10-1996
			CA	2217062 A1	17-10-1996
			CN	1186428 A	01-07-1998
			EP	0820276 A1	28-01-1998
			JP	11503448 T	26-03-1999
			NO	974557 A	02-10-1997
			NZ	305515 A	29-03-1999
			WO	9632095 A1	17-10-1996
			US	6221398 B1	24-04-2001
			ZA	9602596 A	14-10-1996
WO 0038811	A	06-07-2000	AU	1877100 A	31-07-2000
			BR	9916587 A	25-09-2001
			EP	1144065 A1	17-10-2001
			WO	0038811 A1	06-07-2000
			NO	20013039 A	22-08-2001
WO 0044468	A	03-08-2000	AU	2513300 A	18-08-2000
			WO	0044468 A1	03-08-2000
			US	6302958 B1	16-10-2001